A phase Ib/II clinical trial of AMY-101 in patients with the rare diseases PNH (Paroxysmal Nocturnal Hemoglobinuria).

Trial Profile

A phase Ib/II clinical trial of AMY-101 in patients with the rare diseases PNH (Paroxysmal Nocturnal Hemoglobinuria).

Planning
Phase of Trial: Phase I/II

Latest Information Update: 18 Dec 2017

At a glance

  • Drugs AMY 101 (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Dec 2017 New trial record
    • 13 Dec 2017 According to a Amyndas Pharmaceuticals media release, company is now planning to initiate Phase Ib/II clinical trials in patients with the rare diseases C3G and PNH for which AMY-101 has received orphan designation from the FDA and the EMA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top